CEFTIN FOR ORAL SUSPENSION
110538
Approved/Revised 04-Apr-2007
Material
SDS Number
Version 12
GlaxoSmithKline, Corporate Environment, Health & Safety
Company Name
980 Great West Road
+44-20-8047-5000
UK General Information:
+44-1865-407333
Transport Emergency (EU)
+1-612-221-3999, Ext 221
Medical Emergency
US number, available 24 hours
Information and Advice:
Multi-language response
Brentford, Middlesex TW8 9GS UK
+1-888-825-5249
US General Information:
+1-703-527-3887
Transport Emergency (non EU)
US number, available 24 hours
Multi-language response
One Franklin Plaza, 200 N 16th Street
GlaxoSmithKline, Corporate Environment, Health & Safety
Philadelphia, PA 19102-1225 US
Percentage
CAS RN
Ingredients
3.5 to 7.5
64544-07-6
CEFUROXIME AXETIL
92.5 to 96.5
Unassigned
NON-HAZARDOUS INGREDIENTS
Fire and Explosion
Assume that this product is capable of sustaining combustion.
SAFETY DATA SHEET
1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE
COMPANY/UNDERTAKING
2. COMPOSITION / INFORMATION ON INGREDIENTS
3. HAZARDS IDENTIFICATION
Synonyms
CEFTIN SUSPENSION 125 MG/5 ML * CEFTIN SUSPENSION 250 MG/5 ML *
CEFTIN ORAL SUSPENSION * CEFTUM ORAL SUSPENSION 125 MG/5 ML
* CEFUROX ORAL SUSPENSION * CEFOCEF ORAL SUSPENSION *
ELOBACT ORAL SUSPENSION * ELOBACT GRANULES * ELOBACT 125 MG
DOSIERBRIEFE * ZINADOL ORAL SUSPENSION * ZINAT SUSPENSION *
ZINNAT SUSPENSION SACHET 125 MG * ZINNAT SUSPENSION 25 MG/ML
* ZINACEF SUSPENSION * ZIPOS ORAL SUSPENSION * ZOREF ORAL
SUSPENSION * NDC NO 0173-0740-00 * NDC NO 0173-0741-00 * NDC NO
0173-0741-10 * CEFUROXIME AXETIL, FORMULATED PRODUCT
Material
CEFTIN FOR ORAL SUSPENSION
Page 1 / 6
CEFTIN FOR ORAL SUSPENSION
110538
Approved/Revised 04-Apr-2007
Material
SDS Number
Version 12
Health
Exposure might occur via skin; eyes; ingestion; inhalation.
May produce allergic skin reactions.
Respiratory allergen.
Possible effects of overexposure in the workplace include: symptoms of
hypersensitivity (such as skin rash, hives, itching, and difficulty breathing);
nausea